Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (318)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (26)
Diagnostics guidance (7)
Health technology evaluations (13)
Highly specialised technologies guidance (6)
Interventional procedures guidance (15)
Medical technologies guidance (9)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (318)
Apply filters
Showing 91 to 100 of 318
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Technology appraisal guidance
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Technology appraisal guidance
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Technology appraisal guidance
TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]
Technology appraisal guidance
4 February 2026
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317
Technology appraisal guidance
TBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Technology appraisal guidance
TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]
Technology appraisal guidance
29 July 2026
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Technology appraisal guidance
TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]
Technology appraisal guidance
TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
Technology appraisal guidance
TBC
Previous page
1
…
8
9
Current page
10
11
12
…
32
Page
10
of
32
Next page
Results per page
10
25
50
All
Back to top